Ge Long Hui A P P·2025-09-25 08:55Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the clinical trial of LXH-1211 tablets, a novel compound designed for pulmonary arterial hypertension treatment [1] Group 1: Product Development - LXH-1211 is a structurally innovative compound targeting the clinical manifestations and pathological essence of pulmonary arterial hypertension [1] - The research indicates that LXH-1211 has a dual mechanism of action, stimulating soluble guanylate cyclase (sGC) to induce vasodilation and reduce pulmonary arterial hypertension, while also inhibiting AMP-activated protein kinase (AMPK) to prevent vascular remodeling and fibrosis [1] - The proposed clinical indication for LXH-1211 is the treatment of pulmonary arterial hypertension [1]